Login to Your Account



Pfizer Employs Pricing Ploy

FDA Gives Nod to Protalix's Elelyso in Gaucher Disease

By Marie Powers
Staff Writer

Wednesday, May 9, 2012
Last week, the FDA increased the options available in Type I Gaucher disease by approving Elelyso (taliglucerase alfa), a recombinant version of the hydrolytic human lysosomal enzyme glucocerebrosidase. The compound was discovered by Protalix BioTherapeutics Inc., which is partnered with Pfizer Inc. on development and commercialization outside Israel.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription